[Skip to Content]
[Skip to Content Landing]
Views 511
Citations 0
Observation
May 2018

Rechallenge With Nivolumab After Vemurafenib Treatment of Initially Nivolumab-Resistant Advanced Melanoma

Author Affiliations
  • 1Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
  • 2Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
JAMA Dermatol. 2018;154(5):621-622. doi:10.1001/jamadermatol.2017.6400

BRAF inhibitors (BRAFis) have prolonged the survival of patients with advanced BRAF-mutated melanoma. Recent reports suggest that BRAFis not only inhibit growth signal of melanoma cells but also play an immunomodulatory role by affecting tumor-infiltrating lymphocytes and the expression of programmed cell death ligand 1 (PD-L1) and major histocompatibility complex (MHC) in melanoma cells.1,2 Herein, we report a case of melanoma, which was initially resistant to nivolumab treatment, but showed a remarkable response to rechallenge with nivolumab after vemurafenib therapy.

×